白河厚生総合病院は、福島県白河市にある、JA福島厚生連が運営する医療機関。全国厚生農業協同組合連合会の病院の一つである。

During the past decade, Shirakawa Kosei General Hospital conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Shirakawa Kosei General Hospital" are "Atrial Fibrillation" (1 trials), "Chronic Kidney Disease" (1 trials), "Prevention of Stroke or Systemic Embolism" (1 trials) and "Type 2 Diabetes Mellitus" (1 trials). Many other conditions were trialed in "Shirakawa Kosei General Hospital" in a lesser frequency.

Most popular intervention types in "Shirakawa Kosei General Hospital" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Apixaban" (1 trials), "Apixaban matching placebo" (1 trials), "Asundexian (BAY2433334)" (1 trials), "Asundexian matching placebo" (1 trials) and "Finerenone (Kerendia, BAY94-8862)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Shirakawa Kosei General Hospital" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Shirakawa Kosei General Hospital". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Shirakawa Kosei General Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Shirakawa Kosei General Hospital, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".